AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| AbbVie (NYSE: ABBV) | Delayed: 284.80 -4.28 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $289.08 | 52 Week High | $68.12 | |||
| Open | $287.63 | 52 Week Low | $50.71 | |||
| Day High | $289.00 | P/E | 61.78 | |||
| Day Low | $282.15 | EPS | $4.61 | |||
| Volume | 4,394,198 | |||||
